Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan

        -Spectral joins leading Japanese medical centres in presenting data
                 on clinical utility of EAA(TM) diagnostic-

    TORONTO, Feb. 28 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today
announced that it will present new findings demonstrating the clinical utility
of its EAA(TM) Endotoxin Activity Assay, the only FDA cleared diagnostic for
the measurement of endotoxin, at the 12th Annual Critical Care for Endotoxemia
congress. The conference takes place in Fukuoka, Japan from February
28th-29th, 2008 and focuses on the role of endotoxemia in sepsis in critically
ill patients. The Company and a number of leading medical centres in Japan
including the Tokyo Medical Clinic, Osaka City General Hospital and Iwate
Medical University will each present findings using data collected with
Spectral's EAA(TM) product that highlight the clinical utility of the
    "More than one-third of the presentations being given at this important
conference use data collected with our EAA(TM) and highlight the value of our
product. With Japan being one of the leading nations that emphasize the
importance of endotoxin and its role in sepsis, our unique EAA(TM) diagnostic
plays a prominent role in patient care," said Dr. Paul Walker, President and
CEO of Spectral Diagnostics. "This data supports our expanded distribution
relationship with Toray, which commenced last quarter. Toray's therapeutic
column, Toraymyxin, is highly effective in removing endotoxin from the
bloodstream and together with EAA(TM) has been recognized in Japan as a
valuable combination for the diagnosis, treatment and monitoring of patients
with endotoxemia."
    Debra Foster, Director of Spectral's Sepsis Program, will present Friday
February 29th at 8:30am Japanese Standard Time. Following the conference, the
findings presented will be published in the Japan Journal for Critical Care
for Endotoxemia.

    About Spectral Diagnostics

    Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral's lead product is its EAA(TM) Endotoxin Activity
Assay, the only FDA approved diagnostic for the measurement of endotoxin.
Spectral technologies provide accurate and timely information to clinicians
enabling the early initiation of appropriate and targeted therapy. Spectral is
listed on TSX under the symbol SDI.

    Forward-looking statement

    Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.

    %SEDAR: 00002006E

For further information:

For further information: Dr. Paul Walker, President & CEO, (416)
626-3233 ext. 2100; James Smith, Investor Relations, (416) 815-0700 ext. 229,

Organization Profile

Spectral Diagnostics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890